BAC
Bank of America Corporation
BAC has the edge over CNA overall, supported by stronger modeled upside and stronger valuation.
CNA
CNA Financial Corporation
CNA trails on the overall score without a compensating advantage in the available component scores.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
CNA's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNA.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over CNA in the historical PE scenario, which offers more potential upside but is not a forecast.
CNA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.8x | $37.32 | -23% |
| Fair | 11x | $42.60 | -12% |
| Forward | 11x | $48.29 | — |
| Current | 13x | $48.29 | — |
| Expensive | 15x | $55.76 | +15% |
Historical ranges are pointers, not guarantees.
CNA's PE is in its expensive range at 13x. On analysts' estimates for next year's earnings, today's price would be 11x, in its fair range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CNA on the outlook, with more favorable earnings and profitability expectations.
CNA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Decline | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect CNA's revenue to grow, but its earnings and profitability to decline.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CNA on earnings, with more consistent year-over-year improvement.
CNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.59 | +21% |
| Q3 2026 | $3.79 | +3.8% |
| Q2 2026 | $4.55 | +42% |
| Q1 2026 | $4.47 | +36% |
| Q4 2025 | $4.69 | +33% |
| Q3 2025 | $3.65 | -24% |
| Q2 2025 | $3.21 | -32% |
| Q1 2025 | $3.28 | -28% |
| Q4 2024 | $3.52 | -21% |
CNA earned $3.79 per share over the past year, up 3.8% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over CNA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over CNA on profitability, with a higher operating margin.
CNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +0.1% |
| Q2 2026 | $3.8B | +3% |
| Q1 2026 | $3.7B | +1.4% |
| Q4 2025 | $3.8B | +3.8% |
| Q3 2025 | $3.8B | +5.5% |
| Q2 2025 | $3.7B | +5.6% |
| Q1 2025 | $3.6B | +5.3% |
| Q4 2024 | $3.7B | +5.2% |
CNA's revenue has grown year over year for 16 quarters in a row: $3.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | -7.2 points |
| Q2 2026 | 11% | +0.4 points |
| Q1 2026 | 7.3% | -2.4 points |
| Q4 2025 | 9.9% | +9.3 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 10% | -1.2 points |
| Q1 2025 | 9.6% | -2.8 points |
| Q4 2024 | 0.6% | -13 points |
CNA's operating margin was 6.2% last quarter, down 7.2 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over CNA on cash flow, with more consistent year-over-year improvement.
CNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $634M | -9.9% |
| Q2 2026 | $629M | +17% |
| Q1 2026 | $380M | -39% |
| Q4 2025 | $542M | -18% |
| Q3 2025 | $704M | -3.6% |
| Q2 2025 | $538M | -9.9% |
| Q1 2025 | $620M | +28% |
| Q4 2024 | $665M | +34% |
CNA's free cash flow was $2.2B over the past year, down 14% from the year before. Free cash flow isn't a meaningful measure for financial services companies like CNA.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | -0.1% | -300K shares |
| 3 years | -0.1% | -300K shares |
| 5 years | -0.3% | -700K shares |
| Available history | -0.2% | -500K shares |
CNA has 272M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $36M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $34M |
| Q4 2024 | — |
CNA spent $36M buying back its own shares over the past year, up 5.9% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.0x | Healthy |
CNA has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.0 | Neutral |
| Stochastic | 35.9 | Neutral |
CNA's weekly RSI is 51 (neutral) and its Stochastic is 36 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over CNA on valuation relative to its sector.
CNA PE vs Financial Services Sector
| Metric | CNA | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 2.2% below |
| PE % | 68 | 63 | 5 pts above |
CNA is trading at 13x earnings, in line with the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 1.9% above |
| 20 week MA | $49.3 | 2% below |
| 50 week MA | $47.6 | 1.5% above |
| 100 week MA | $47.4 | 1.9% above |
| 200 week MA | $45.4 | 6.4% above |
CNA has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
CNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $38.6 | -13% |
| 2021 | $38.6 | $43.8 | +13% |
| 2022 | $43.8 | $41.9 | -4.4% |
| 2023 | $41.9 | $42.3 | +1.1% |
| 2024 | $42.3 | $48.4 | +14% |
| 2025 | $48.4 | $47.8 | -1.3% |
| 2026 YTD | $47.8 | $48.3 | +1.1% |
CNA has the edge over BAC on returns for 2026, with the stronger performance.